induc
interferon
product
immunomodul
activ
intracellular
enzym
rnasel
viral
rna
transcript
antivir
hemispherx
enter
collabor
red
laboratori
red
laboratori
nv
expect
facilit
continu
develop
ampligen
hemispherx
also
enter
agreement
schere
plough
use
schere
facil
princip
manufactur
platform
us
agreement
may
expand
includ
territori
hemispherx
aop
orphan
pharmaceut
sign
market
agreement
ampligen
treatment
chronic
fatigu
syndrom
austria
czech
republ
poland
hungari
arrang
hemispherx
bioclon
bioclon
certain
market
right
ampligen
southern
hemispher
uk
ireland
us
ampligen
grant
orphan
drug
statu
treatment
aid
renal
cell
carcinoma
phase
ii
complet
chronic
fatigu
syndrom
phase
iii
invasivemetastat
malign
melanoma
phase
ii
august
hemispherx
announc
intend
use
proce
privat
placement
compani
stock
complet
clinic
work
immunotherapeut
antivir
ampligen
previous
hemispherx
submit
applic
emea
approv
ampligen
treatment
chronic
fatigu
syndrom
first
stage
regulatori
review
clear
hemispherx
europ
hemispherx
obtain
orphan
drug
statu
ampligen
treatment
chronic
fatigu
syndrom
eu
provid
hemispherx
year
market
exclus
follow
launch
drug
well
potenti
financi
research
benefit
agent
februari
crystaal
corpor
biovail
pharmaceut
canada
acquir
exclus
market
right
ampligen
canada
submit
nda
agent
treatment
chronic
fatigu
syndrom
meantim
ampligen
avail
sinc
may
canadian
emerg
drug
releas
programm
treatment
chronic
fatigu
syndrom
immun
dysfunct
syndrom
rivex
pharma
helix
biopharma
bioclon
initi
clinic
studi
ampligen
treatment
chronic
fatigu
syndrom
australia
activ
substanc
ampligen
manufactur
fh
fauld
ltd
clinic
treatment
programm
chronic
fatigu
syndrom
pacif
rim
countri
plan
ampligen
avail
sever
chronic
fatigu
syndrom
name
patient
costrecoveri
basi
south
africa
hemispherx
develop
readytous
liquid
formul
drug
begun
treat
patient
chronic
fatigu
syndrom
ongo
clinic
trial
hemispherx
also
develop
oral
version
drug
oragen
undergo
preclin
evalu
februari
hemispherx
biopharma
announc
initi
phase
iiiii
trial
ampligen
treatment
latestag
multidrugresist
strain
hiv
european
union
patient
treat
studi
exhaust
treatment
option
juli
hemispherx
state
ampligen
evalu
phase
iib
trial
patient
hiv
us
trial
compris
two
studi
rearmi
rearmii
researchevalu
ampligen
retrovir
mutat
ii
evalu
abil
ampligen
prevent
emerg
mutat
drugresist
strain
viru
sever
hundr
patient
current
antiretrovir
therapi
risk
viral
relaps
enrol
centr
connecticut
new
york
florida
california
second
phase
iib
studi
evalu
effect
ampligen
structur
treatment
interrupt
sti
also
underway
final
result
studi
report
decemb
nih
sponsor
studi
potenti
therapi
sar
identifi
ampligen
unusu
high
consist
antivir
activ
human
coronaviru
pathogen
implic
caus
agent
diseas
ampligen
demonstr
high
potenc
low
concentr
ml
favour
safeti
profil
octob
hemispherx
announc
base
proms
new
result
compani
stockpil
inject
andor
oral
format
ampligen
alferon
n
independ
research
demonstr
antivir
activ
ampligen
flavivirus
west
nile
viru
equin
enceph
viru
dengu
fever
viru
japanes
enceph
viru
well
viru
class
associ
bioterror
anim
studi
ampligen
shown
prevent
destruct
nerv
cell
reduc
viru
concentr
brain
blood
stream
increas
surviv
rate
research
rega
institut
belgium
publish
result
anim
studi
demonstr
ampligen
superior
protect
mice
coxsacki
virusinduc
myocard
compar
pegyl
interferon
may
hemispherx
announc
file
expand
us
patent
applic
cover
use
ampligen
potenti
treatment
prevent
sever
acut
respiratori
syndrom
sar
dread
emerg
virus
combin
therapi
zidovudin
ampligen
toxic
similar
caus
zidovudin
alon
studi
compar
ampligen
placebo
zidovudin
recipi
total
number
clinic
trial
hivinfect
paadvers
event
differ
significantli
tient
receiv
iv
infus
mismatch
doubletreat
group
strand
rna
dose
level
mgm
dose
patient
undergo
structur
frequent
advers
event
flush
treatment
interrupt
sti
haart
advers
chill
fever
tight
chest
dyspnoea
flulik
sympev
associ
ampligen
mild
tom
nausea
reaction
selflimit
selflimit
incid
insulin
reand
gener
subsid
infus
comsist
hyperlipidaemia
advers
chang
plete
infus
usual
accompani
tranlact
acid
level
sient
leucopenia
leucocytosi
one
patient
receiv
mismatch
doublestrand
rna
common
advers
event
clinic
mgm
discontinu
therapi
develop
trial
metastat
melanoma
patient
includ
flulik
symptom
fatigu
myalgia
headach
fatigu
compar
placebo
randomis
doubleblind
crossov
studi
actg
volmismatch
doublestrand
rna
synergist
unteer
overal
signific
differwith
multipl
antihiv
drug
combin
indic
enc
two
treatment
term
prower
determin
antihiv
agent
alon
duction
interferon
biolog
marker
incombin
mismatch
doublestrand
terferon
lymphocyt
function
lymphocyt
rna
use
doseeffect
analys
calcusyn
prolif
respons
natur
killer
cell
activifor
window
softwar
mismatch
doublestrandti
symptom
score
greater
mismatch
ed
rna
synergist
combin
abadoublestrand
rna
recipi
placebo
cavir
zidovudin
zalcitabin
didanosin
stavurecipi
symptom
mild
natur
dine
efavirenz
indinavir
ritonavir
nelfinavir
betweengroup
differ
signific
amprenavir
synergist
antagonist
day
dose
lamivudin
delavirdin
nevirapin
sain
patient
chronic
fatigu
syndrom
quinavir
ampligen
normalis
upregul
synthetasernas
l
system
clear
human
pharmacodynam
herpesviru
antigenposit
cell
peripher
blood
mononuclear
cell
cultur
preclin
studi
ampligen
reduc
serum
mismatch
doublestrand
tion
return
baselin
level
treatment
disrna
induc
express
physiolog
continu
function
antivir
protect
system
clinic
studi
effect
mismatch
synthetasernas
l
system
cell
vitro
amdoublestrand
rna
immun
function
pligen
inhibit
hivrel
reduct
cell
growth
rate
act
tion
ratio
rang
amsynergist
revers
transcriptas
inhibitor
pligen
also
act
synergist
zidovudin
antisens
oligonucleotid
direct
zidovudineresist
strain
tat
gene
compound
shown
inhibit
human
ampligen
display
synerg
herp
infect
lymphocyt
hiv
vitro
use
combin
concentr
didanosin
contrast
synerg
demonstr
ampligen
zidovudin
combinaalso
activ
rotaviru
mismatch
doublestrand
rna
equal
provement
baselin
activ
wildtyp
hiv
hiv
resist
exercis
perform
measur
bicycl
testnevirapin
proteas
inhibitor
nucleosid
re
oxygen
uptak
improv
lmin
vers
trancriptas
inhibitor
baselin
lmin
treatment
mismatch
doublestrand
rna
cognit
improv
seen
patient
receiv
mismatch
therapeut
trial
doublestrand
rna
measur
use
cognit
subscal
scl
neuropsycholog
cal
function
test
significantli
greater
improvemelanoma
ten
patient
metastat
melano
seen
patient
receiv
mismatch
treat
mismatch
doublestrand
doublestrand
rna
compar
placebo
misrna
openlabel
phase
iii
trial
drug
match
doublestrand
rna
gener
well
administ
iv
low
dose
one
patient
toler
accord
media
releas
high
dose
nine
patient
patient
treat
mismatch
doubleov
minut
twice
weekli
week
strand
rna
experienc
appar
two
patient
receiv
highdos
therapi
complet
clinic
recoveri
month
treatachiev
complet
respons
receiv
mainment
spontan
improv
untreat
paten
therapi
least
month
follow
tient
chronic
fatigu
syndrom
remain
complet
respons
without
therapi
month
mismatch
doublestrand
rna
well
toler
hepat
b
result
phase
iii
studi
chronic
fatigu
syndrom
ampligen
signifimismatch
doublestrand
rna
two
cantli
improv
patient
physic
perform
three
timesweek
eight
patient
chronic
assess
treadmil
exercis
toler
test
hepat
b
indic
drug
may
ett
placebocontrol
phase
iii
antivir
effect
four
patient
lost
hbv
dna
studi
patient
sever
debilit
three
patient
becam
hbeag
seroneg
chronic
fatigu
syndrom
ampligen
twice
week
treatment
none
patient
weekli
superior
placebo
improv
ett
relaps
vs
patient
popul
comresult
phase
studi
actg
plete
week
treatment
also
intentun
confirm
previou
benefici
effect
mistotreat
popul
vs
complet
match
doublestrand
rna
hiv
infect
week
treatment
thirtynin
hivinfect
patient
asymptomatin
randomis
placebocontrol
trial
amic
diseas
earli
arc
receiv
one
six
dose
pligen
therapi
improv
physic
cognit
mismatch
doublestrand
rna
perform
patient
chronic
fatigu
synweek
mismatch
doublestrand
rna
drome
condit
possibl
viral
aetiolosignific
effect
antigenaemia
hiv
gy
viraemia
number
hivinfect
cell
howev
rate
cell
deplet
reduc
belgium
studi
patient
chronic
fatigu
effect
dosedepend
addit
pasyndrom
randomis
receiv
mismatch
tient
develop
opportunist
infect
doublestrand
rna
ampligen
new
hivassoci
symptom
receivtwic
weekli
placebo
week
mismatch
ing
mismatch
doublestrand
rna
doublestrand
rna
significantli
improv
cognit
physic
perform
physic
performin
patient
least
month
previou
anc
activ
daili
live
measur
use
zidovudin
treatment
ampligen
therapi
administh
karnofski
perform
score
show
imter
prior
develop
advanc
stage
symptom
associ
higher
count
second
analysi
median
durat
sti
ampligen
group
week
compar
increas
immun
function
compar
unwith
week
concurr
control
nonamtr
patient
thu
ampligen
appear
pligen
group
activ
zidovudineresist
hiv
strain
phase
iib
studi
amp
patient
studi
conduct
zidovudinetr
hiv
undergo
three
structur
treatment
patient
mismatch
doublestrand
rna
therapi
interrupt
sti
haart
ampligen
effect
initi
earlier
iv
twice
weekli
therapi
result
signific
cours
hiv
diseas
studi
periprolong
control
hiv
viraemia
compar
od
patient
treat
ampligen
untreat
control
patient
taken
haart
twice
weekli
mean
decreas
count
given
ampligen
n
continu
show
compar
placebo
viru
level
copiesml
mean
recipi
ampligen
treat
patient
baselin
week
count
control
group
patient
count
show
mean
increas
n
taken
haart
given
ampligen
count
peak
week
develop
hiv
rebound
within
mean
placebo
recipi
consist
decreas
week
addit
ampligen
group
demonfrom
baselin
chang
ampligen
therapi
strate
increas
cell
suggest
week
placebo
treatment
revers
tion
immunogen
declin
seven
patient
ampligen
recipi
like
exhibit
delayedtyp
hypersensit
respons
less
like
progress
aid
refer
placebo
recipi
